Lily announces significant investment in US operations

Eli Lilly and Company plans to invest $850 million in its US operations this year. These investments will span the company’s US facilities, including research laboratories, manufacturing sites and general and administrative areas.

Details of the investment were unveiled at the company’s Technology Center. Among the investment specifics were details of a new $85 million expansion of the Trulicity (dulaglutide) device assembly operations, which is part of a five-year investment by the company to expand its diabetes products manufacturing operations in the US. These investments also include a $140 million insulin cartridge production facility.

“In addition to providing the capacity necessary for the safe and reliable supply of medicines to patients these investments have allowed us to add US manufacturing jobs,” said Maria Crowe, president of Lilly Manufacturing. “These include highly-skilled technicians, scientists and engineers, which are an economic catalyst for local communities.”

David A. Ricks, Lilly’s president and chief executive officer concluded by saying that the company has invested approximately $5 billion in its US facilities during the last decade and that more investments can be expected, particularly if the US adopts a more favourable tax environment.